Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 0.78 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palazestrant SCHEMBL23280512 | 1.00 | ESR1 (0.78) | ESR1PGR | |
| Palazestrant SCHEMBL24885107 | 1.00 | ESR1 (0.78) | ESR1PGR | |
| Palazestrant SCHEMBL30128723 | 1.00 | ESR1 (0.78) | ESR1PGR | |
| SCHEMBL26424146 | 0.92 | ESR1 (0.67) | ESR1PGR | |
| SCHEMBL30123563 | 0.92 | ESR1 (0.79) | ESR1PGR | |
| SCHEMBL17839179 | 0.92 | ESR1 (0.79) | ESR1PGR | |
| SCHEMBL23280600 | 0.88 | ESR1 (0.75) | ESR1 | |
| SCHEMBL20528169 | 0.88 | ESR1 (0.75) | ESR1 | |
| SCHEMBL29358188 | 0.88 | ESR1 (0.75) | ESR1 | |
| SCHEMBL25002345 | 0.88 | ESR1 (1.00) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | OLEMA PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12370181-B2 | Regimens of estrogen receptor antagonists | OLEMA PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4114391-B1 | COMPOSITIONS FOR USE IN A METHOD OF TREATING AN ESTROGEN RECEPTOR ASSOCIATED CANCER | OLEMA PHARMACEUTICALS INC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250214996-A1 | SALTS AND SOLID FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST | CURIA GLOBAL, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250049768-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | OLEMA PHARMACEUTICALS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024124182-A1 | DOSAGE FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST | OLEMA PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240131013-A1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS INC (US) | 2024-04-25 | — | — | US | disclosed |
| EP-3355884-B1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210059991-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20210059991-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10624878-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10624878-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190247372-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190247372-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10292971-B2 | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10292971-B2 | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180289679-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624878-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885PGR 9/4885 |
| US-20190247372-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885PGR 9/4885 |
| US-12370181-B2 | Regimens of estrogen receptor antagonists | ESR1, GPER1, ESR2 | ESR1 1/4885PGR 5/4885 |
| US-20250214996-A1 | SALTS AND SOLID FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST | ESR1, ESR2, ESRRA | ESR1 1/4885PGR 7/4885 |
| US-20240131013-A1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885PGR 9/4885 |
| US-10292971-B2 | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885PGR 9/4885 |
| US-20180289679-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885PGR 9/4885 |
| US-20250049768-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | GPER1, ESR1, ESRRA | ESR1 2/4885PGR 8/4885 |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885PGR 9/4885 |
| US-20210059991-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885PGR 9/4885 |
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | ESR1, ESR2, PGR | ESR1 1/4885PGR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.